CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Glioma Actively Personalized Vaccine Consortium (GAPVAC) focuses on developing personalized immunotherapy for glioblastoma patients. It aims to create a tailored peptide-based vaccine using advanced genomic and proteomic techniques to improve treatment outcomes.
Glioblastoma (GBM) is a rare (2-3 incidences in 100,000) and fatal disease.
Each year, approximately 13,000 new cases of GBM are diagnosed in Europe.
The 5-year survival rate of this highly aggressive tumor entity under conventional therapy is less than 6%.
Currently available therapeutic options neglect the individuality of each patients’ disease and only temporarily influence tumor progression with poor effect on overall survival.
Introduction of novel highly innovative personalized approaches…
IMMATICS BIOTECHNOLOGIES GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Glasgow
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Hillerod
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Germany, Mainz
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Tuebingen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
